title: Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay.
abstract: The effect of pretreatment with antitumor drugs on lymphokine-activated killer (LAK) cell cytotoxic activity, determined by lactate-dehydrogenase(LDH)-release assay, was investigated. LAK cells were induced by incubating peripheral blood lymphocytes of healthy donors in medium containing interleukin-2 (IL-2) and monoclonal anti-CD3 antibody for 6-7 days. A human lung squamous carcinoma cell line, SQ-5, was used as an adherent target. After 24 h exposure of the target cells to cisplatin, doxorubicin, or mitomycin C, the drugs were washed off and LAK cells were added at an E/T ratio of 5. During further incubation for 48 h, LDH release from cisplatin- or doxorubicin-pretreated target cells was markedly higher than that from non-pretreated target cells. The combination of cisplatin and LAK cells has an additive cytotoxic effect and that of mitomycin C and LAK cells does not; there may also be an additive effect late in the toxicity mechanism between doxorubicin and LAK cells.
authors.affiliation: RIKEN Cell Bank, Institute of Physical and Chemical Research (RIKEN), Ibaraki, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kawai
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Saijo-Kurita
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: K
authors.initials: K
authors.lastname: Koiso
authors.forename: T
authors.initials: T
authors.lastname: Ohno
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000201:enzymology / Q000473:pathology / Q000628:therapy; D016923:Cell Death / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004796:Clinical Enzyme Tests / Q000379:methods; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D004357:Drug Synergism; D006801:Humans; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology*; D007770:L-Lactate Dehydrogenase / Q000032:analysis / Q000378:metabolism*; D008175:Lung Neoplasms / Q000201:enzymology / Q000473:pathology / Q000628:therapy; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000201:enzymology
chemical_list: D000970:Antineoplastic Agents; D007770:L-Lactate Dehydrogenase